Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients

Patients with non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions and L858R) benefit from EGFR tyrosine kinase inhibitors (TKIs). However, some researchers have reported that responses to TKIs differ by subtypes of EGFR exon 19 muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Jian, Zhong, Wenzhao, Zhang, Xuchao, Huang, Ying, Yan, Honghong, Yang, Jinji, Dong, Zhongyi, Xie, Zhi, Zhou, Qing, Huang, Xiaosui, Lu, Danxia, Yan, Wenqing, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762318/
https://www.ncbi.nlm.nih.gov/pubmed/29340050
http://dx.doi.org/10.18632/oncotarget.22768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762318/
https://www.ncbi.nlm.nih.gov/pubmed/29340050
http://dx.doi.org/10.18632/oncotarget.22768

Ejemplares similares